ArticleBMC rheumatology2024

Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data.

Marina G Birck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.